NBIO - Nascent Biotech Moves Corporate Offices to San Diego
San Diego, CA, April 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO) has moved their corporate offices to San Diego, CA.
Nascent CEO Sean Carrick stated, “This is a strategic as well as a fiscal management move that puts our corporate offices close to our R&D Laboratory, as well where we will be performing our Phase I Human Clinical trial for brain cancer. The move will also place our Headquarters in a major biotech center in the United States, placing the company in a more beneficial position to capitalize on expertise and resources of the location in the further development and clinical trials of our antibody.”
About Nascent Biotech, Inc.:
Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an Investigational New Drug (IND) application cleared by the FDA for Phase 1 clinical trials in brain cancer. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Safe Harbor:
Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on October 28, 2014, and subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Information:
Nascent Biotech, Inc.
Sean Carrick
President |CEO
772.713.0541
sean.carrick@nascentbiotech.com